NAFLD is a common liver disease with extensive fat build up in liver. Some patients continue to progress to more severe liver damage, manifested by lobular inflammation, hepatocyte damage and fibrosis, as knowns as NASH. Abnormal liver fat accumulation by itself associates with more risks of cardiovascular diseases. In addition, NASH can progress to more serious, life-threatening clinical outcomes, including cirrhosis, hepatocellular carcinoma, liver transplantation, and even death.
The growing prevalence of NAFLD and NASH parallels with the dramatic rise in population of obesity and metabolic syndrome in global and China. One study estimated 25% people worldwide have NAFLD, and by 2030 there will be 27M and 48M NASH patients in China and U.S., respectively.
Treatment for NASH is limited to life style modification. No pharmacological treatment has been approved in major market yet.